Clinical Trial Update: Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating empagliflozin as a modulator of systemic vascular resistance and cardiac output in patients with type 2 diabetes; the study status is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin) (empagliflozin)

Snippet

Sponsor: RWTH Aachen University | Conditions: Diabetes Mellitus Type 2 (T2DM) | Phase 2 | Status: COMPLETED